Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Explore the Coyote V8’s development, all-generation updates, supercharged variants, and common issues that make this Ford ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback